243 related articles for article (PubMed ID: 22289497)
1. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
McDevitt MA
Semin Oncol; 2012 Feb; 39(1):109-22. PubMed ID: 22289497
[TBL] [Abstract][Full Text] [Related]
2. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes.
Benetatos L; Hatzimichael E; Dasoula A; Dranitsaris G; Tsiara S; Syrrou M; Georgiou I; Bourantas KL
Leuk Res; 2010 Feb; 34(2):148-53. PubMed ID: 19595458
[TBL] [Abstract][Full Text] [Related]
3. The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.
Tan PT; Wei AH
Pathology; 2011 Oct; 43(6):536-46. PubMed ID: 21881538
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
Benetatos L; Dasoula A; Hatzimichael E; Syed N; Voukelatou M; Dranitsaris G; Bourantas KL; Crook T
Ann Hematol; 2011 Sep; 90(9):1037-45. PubMed ID: 21340720
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P
Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.
Galm O; Wilop S; Lüders C; Jost E; Gehbauer G; Herman JG; Osieka R
Ann Hematol; 2005 Dec; 84 Suppl 1():39-46. PubMed ID: 16231140
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
Sieglová Z; Zilovcová S; Cermák J; Ríhová H; Brezinová D; Dvoráková R; Marková M; Maaloufová J; Sajdová J; Brezinová J; Zemanová Z; Michalová K
Leuk Res; 2004 Oct; 28(10):1013-21. PubMed ID: 15289012
[TBL] [Abstract][Full Text] [Related]
11. Gene silencing by DNA methylation in haematological malignancies.
Boultwood J; Wainscoat JS
Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
[TBL] [Abstract][Full Text] [Related]
12. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
Larsson CA; Cote G; Quintás-Cardama A
Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
[TBL] [Abstract][Full Text] [Related]
13. The role of mutations in epigenetic regulators in myeloid malignancies.
Shih AH; Abdel-Wahab O; Patel JP; Levine RL
Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling in MDS and AML: potential and future avenues.
Theilgaard-Mönch K; Boultwood J; Ferrari S; Giannopoulos K; Hernandez-Rivas JM; Kohlmann A; Morgan M; Porse B; Tagliafico E; Zwaan CM; Wainscoat J; Van den Heuvel-Eibrink MM; Mills K; Bullinger L
Leukemia; 2011 Jun; 25(6):909-20. PubMed ID: 21445077
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
Shi H; Guo J; Duff DJ; Rahmatpanah F; Chitima-Matsiga R; Al-Kuhlani M; Taylor KH; Sjahputera O; Andreski M; Wooldridge JE; Caldwell CW
Carcinogenesis; 2007 Jan; 28(1):60-70. PubMed ID: 16774933
[TBL] [Abstract][Full Text] [Related]
17. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.
Ossenkoppele GJ; van de Loosdrecht AA; Schuurhuis GJ
Br J Haematol; 2011 May; 153(4):421-36. PubMed ID: 21385170
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation as a pathogenic event and as a therapeutic target in AML.
Schoofs T; Müller-Tidow C
Cancer Treat Rev; 2011; 37 Suppl 1():S13-8. PubMed ID: 21612874
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Epigenetic Modifications in Myeloid Malignancies.
Venney D; Mohd-Sarip A; Mills KI
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]